SHIELD THERAPEUTICS PLC — Remuneration Information 2016

Sep 13, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6727J

Shield Therapeutics PLC

13 September 2016

Shield Therapeutics plc

("Shield" or the "Company")

Grant of Share Awards

London, UK,  13th September 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that, following approval at the AGM on 4th August 2016,  it has granted awards in the form of options over ordinary shares in the capital of the Company ("Award Shares") to the following executives under its Long Term Incentive Plan ("LTIP").

Carl Sterritt:                                       Director                               92,767

Richard Jones:                                   Director                               67,610

Paul Steckler                                      PDMR                                  58,176

Angela Hildreth                                 PDMR                                  34,591

In total awards have now been granted over 2,026,725 shares under the LTIP. The exercise price per Award Share is 1.5 pence and awards are exercisable between February 2019 and February 2026, subject to applicable performance conditions having been satisfied. The grant of awards is part of the Company's long-term incentive arrangements designed to directly align the interest of the shareholders and executives.

The Company's LTIP was adopted by the Board on 12th February 2016. The LTIP provides for awards of ordinary shares to be made to eligible employees. The arrangements are described more fully in the Admission Document, a copy of which is available on the Company's website (www.shieldtherapeutics.com).

-Ends-

For further information please contact:

Shield Therapeutics plc	+44 (0)191 511 8507
Carl Sterritt, Chief Executive Officer Richard Jones, Chief Financial Officer
Nominated Adviser and Sole Broker Liberum Capital Limited Christopher Britton Steve Pearce Jamil Miah	+44 (0)20 3100 2222
Financial PR Advisor Consilium Strategic Communications	+44 (0)203 709 5700 shieldtherapeutics@consilium-comms.com
Mary-Jane Elliott Matthew Neal Lindsey Neville Hendrik Thys

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. The Company has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) which has exclusive IP rights until 2034. In addition, the Company is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtherapeutics.com.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Carl Sterritt:                       Director / PDMR Richard Jones:                   Director / PDMR Paul Steckler                      PDMR    Angela Hildreth                 PDMR
2	Reason for the notification
a)	Position/status	All PDMRs of Shield Therapeutics
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Shield Therapeutics plc
b)	LEI	n/a
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Option over ordinary shares of 1.5p each in the capital of the Company ISIN of Ordinary Shares: GB00BYV81293
b)	Nature of the transaction	Grant of Options over ordinary shares in accordance with the Company's Long Term Incentive Plan
c)	Price(s) and volume(s)	Exercise price: 1.5p Volumes: Carl Sterritt:                       92,767 Richard Jones:                   67,610 Paul Steckler                     58,176 Angela Hildreth                                34,591
d)	Aggregated information -      Aggregated volume -    Price	253,144 Exercise price: 1.5p
e)	Date of the transaction	12 September 2016
f)	Place of the transaction	Outside a trading venue

Name of authorised official of issuer responsible for making notification.

Richard Jones

CFO and Company Secretary to Shield Therapeutics plc

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHLJMPTMBTBMBF

//<![CDATA[$.ajaxSetup({headers: {'__RequestVerificationToken':'Vw7d_GAZdVNK_SdW3XxJl57OTTqjXe6TX3y7CGkNFu7bGJ3qRcu8Yuax-cUp2v705AFU5VfL_8d-6uEJOkhdB0WJyJED1Isp5tvcOHchwIU1:HPcWPAsHZRWkB9dYwZezK9Ek2U3Xudi-B-e3_dDjtFFlxPeisEpeYHS9ToKl6aMB8_a0o4rGI4QnwgYCrkXlpKDXSyrGmHx92ip5yjtB8XM1'}});//]]>